Approved Products

Boehringer Ingelheim is taking on cancer with our approved therapies for patients with NSCLC, afatinib* and nintedanib**. To learn about our investigational compounds click here.

Compound and target LATEST DEVELOPMENT PHASE (FEBRUARY 2021)
Phase I Phase II Phase III Approved
Approved therapies

References

1

Prescribing Information: GIOTRIF®. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf (Accessed: February 2021).

2

Prescribing Information: VARGATEF®. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: February 2021).

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; NSCLC: non-small-cell lung carcinoma; PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: February 2021